Novartis entered 2026 as a more focused company than the group Vasant Narasimhan inherited eight years earlier. Consumer health, eye care and the Sandoz generics business had been separated, leaving an organisation centred on innovative medicines. The strategic simplification was intended to improve capital allocation and make research productivity easier to judge. The first quarter showed why that clarity is now unforgiving.
Sales of $13.1 billion fell 5 per cent at constant currencies and operating income declined 11 per cent to $4.24 billion. Core operating income was down 14 per cent. Novartis maintained guidance for low-single-digit sales growth across the year, even as US generic competition weighed on important products. It also completed the acquisition of Avidity Biosciences, adding a new platform and pipeline to its development portfolio.
Narasimhan's next test is no longer whether he can reshape the corporate perimeter. He has done that. It is whether the focused company can repeatedly replace revenue lost to patent expiry with medicines that reach patients, win reimbursement and scale. In pharmaceuticals, strategic clarity does not suspend the product cycle. It makes the quality of each launch more visible.
A simpler portfolio raises the performance bar
Conglomerate structures can obscure the economics of drug development. A mature business may provide cash while a research division absorbs it, and investors can struggle to identify where returns are created. By concentrating Novartis on innovative medicines, Narasimhan made a case that scientific focus and disciplined investment would produce better growth and margins.
The benefits are real. Management can direct capital towards a smaller set of therapeutic and technology priorities. Commercial teams can be organised around specialist prescribers and major launches. Transactions can be judged against a clear strategic map rather than a broad collection of healthcare assets. The company can also return cash when internal or external projects do not meet its thresholds.
The cost of focus is concentration. When a major medicine faces competition or a trial disappoints, there is no diversified operating division to soften the result. Novartis must keep its pipeline and business-development engine productive enough to renew the portfolio. Investors can compare research spending with approvals, launches and risk-adjusted future sales more directly.
The first-quarter decline therefore matters beyond a single period. Generic erosion is an expected feature of the industry, not a surprise. The leadership question is whether Novartis scheduled enough new growth before it arrived and whether current launches can ramp fast enough to maintain the group's financial trajectory.
The patent cycle is a race against time
Successful medicines enjoy years of exclusivity, high margins and growing clinical adoption. When patents or regulatory protections end, lower-priced competition can remove revenue quickly, particularly in the United States. The cash generated during exclusivity must finance the next generation of products. A pharmaceutical company that misjudges the timing can face a growth gap even with scientifically promising assets.
Narasimhan has sought to build a set of growth drivers across cardiovascular disease, immunology, neuroscience and oncology. The objective is not merely to launch more medicines, but to build franchises with clear differentiation and large enough patient populations. New products have to earn physician confidence, secure payer coverage and fit into treatment pathways that are already crowded.
Commercial execution begins before approval. Novartis needs strong evidence on outcomes, safety and health economics. It must identify patients who are eligible and ensure diagnostics or delivery capacity exists. After approval, supply must scale reliably and field teams must communicate evidence without overreaching. Delays at any point can waste the limited period before competitors arrive.
The US market is particularly important because of its pricing and volume, but dependence on it creates policy and reimbursement risk. Europe, Japan and emerging Asian markets offer significant patient demand with different access systems. A launch plan has to be global without assuming that one price, evidence package or channel works everywhere.
Avidity adds science and execution risk
The Avidity acquisition expands Novartis's reach into RNA-targeted therapies designed to reach muscle tissue. The scientific proposition is attractive: use antibody-based delivery to carry oligonucleotide medicines into cells where genetic disease can be addressed more directly. The commercial appeal lies in serious disorders with high unmet need and the possibility of platform reuse.
Buying a biotechnology company, however, purchases probability rather than certain revenue. Programmes still have to demonstrate benefit in larger trials, satisfy regulators and reach patients through specialist care. Platform value can be overstated if each medicine presents different delivery, safety or manufacturing challenges. Narasimhan must preserve Avidity's scientific speed while applying the clinical and operational discipline of a global company.
The acquisition also increases the return required from the pipeline. Capital spent externally has an opportunity cost: it could have supported another deal, internal development, dividends or repurchases. Novartis should report progress in terms that allow investors to distinguish scientific milestones from genuine reductions in risk.
Integration is most successful when it removes obstacles rather than layers process onto researchers. Novartis can contribute trial infrastructure, regulatory experience, manufacturing and global commercial reach. It should avoid slowing decision-making or losing the people whose expertise created the assets. Narasimhan's background as a physician and drug developer gives him credibility here; the organisational outcome will show whether that translates into practice.
Launch economics depend on access
A medicine can be clinically successful and commercially disappointing if patients cannot obtain it. Reimbursement has become a central part of pharmaceutical strategy as governments and insurers scrutinise budgets. Premium pricing requires evidence that a medicine improves outcomes, reduces other costs or addresses a need with few alternatives.
Novartis must design development programmes with those questions in mind. Comparative evidence, durable outcomes and practical administration can determine market adoption. A product that is effective but difficult to deliver may require investment in treatment centres, diagnostics or monitoring. Those capabilities are part of launch cost and should be planned early.
Competition within therapeutic classes is also accelerating. Several companies may pursue the same biological target with different dosing, safety or delivery profiles. Being first can help, but a later medicine can win if it offers a meaningful advantage. Narasimhan needs portfolio choices that anticipate the standard of care at launch, not the one that existed when a programme entered the clinic.
This is where the focused Novartis model should produce an advantage. Capital can be concentrated behind the projects with the strongest evidence and commercial position. The difficult part is stopping programmes that are scientifically interesting but unlikely to generate adequate patient or shareholder value. Discipline is most valuable before sunk costs make decisions emotional.
Asia is both a market and a research system
Asia's importance to Novartis extends beyond sales. The region contains large patient populations, sophisticated health systems, expanding clinical-trial capacity and a rapidly growing biotechnology sector. China, Japan, South Korea, Singapore and India each contribute different capabilities, from discovery and manufacturing to specialist care.
Narasimhan has to operate across divergent regulatory and access environments. Japan remains one of the largest pharmaceutical markets, with high clinical standards and price revisions that require careful lifecycle management. China offers scale and scientific momentum but also policy, pricing and intellectual-property considerations. Southeast Asia and India contain enormous need alongside affordability constraints.
A global development programme that includes Asian patients can improve the relevance and speed of evidence, but trial quality and ethical standards must remain consistent. Novartis can also source innovation from regional biotechnology companies through partnerships and acquisitions. The company should compete for assets on scientific value, not simply join a crowded deal cycle.
Supply resilience is another part of the regional equation. Medicines rely on complex networks for active ingredients, devices and specialised manufacturing. Geographic diversification can reduce concentration risk, while technology transfer and quality control require long-term investment. Launch success is impossible if supply cannot meet demand.
Productivity must be measured over the full portfolio
Research productivity cannot be assessed from one approval or one failed trial. It is the value created across a portfolio relative to the cost and time invested. Narasimhan needs enough independent opportunities that a setback does not derail growth, but not so many that resources are spread across weak projects.
Useful indicators include the number of differentiated late-stage assets, probability-adjusted sales, development cycle times and the return on business-development spending. After launch, prescription growth, access, patient persistence and margin contribution matter more than headline approval counts. The company should also show whether technology platforms produce reusable knowledge and lower the cost of later programmes.
Cost control remains relevant as revenue faces pressure. Novartis can protect earnings through productivity, but cuts that weaken trials, medical affairs or launch preparation can deepen the future gap. The right response to patent erosion is not indiscriminate austerity. It is to remove low-value complexity while protecting the work that creates the next franchise.
The company's full-year guidance implies that later quarters should improve from the first. Delivering that recovery will strengthen confidence in the current launch set. Missing it would raise sharper questions about the timing of the pipeline and the assumptions built into recent acquisitions.
The focused company now has to compound
Vasant Narasimhan has changed what Novartis is. He separated large businesses, narrowed therapeutic priorities and made advanced platforms central to the strategy. Those decisions created a company easier to understand and, in principle, easier to manage. They also removed excuses. Innovative medicines must now produce reliable innovation.
The near-term scorecard is straightforward: stabilise sales through generic pressure, accelerate launches, advance acquired programmes and maintain investment discipline. The longer-term test is harder. Novartis must build a renewal system in which each generation of cash-producing medicines funds the next without recurring growth gaps.
That system requires scientific judgement, commercial execution and balance-sheet restraint. Paying for promising biotechnology can supplement internal research, but it cannot replace it. Margin improvement can create funds, but not if it hollows out development. Global reach can multiply a medicine's value, but only when access and supply are designed for each market.
Narasimhan has completed the visible corporate surgery. The next stage will be judged molecule by molecule and launch by launch. If new franchises outrun the patent cycle, Novartis can justify the pure-play model as a durable compounding business. If they do not, strategic simplicity will merely make the shortfall impossible to hide.
